1.39
1.46%
+0.02
Handel nachbörslich:
1.39
AvroBio Inc Aktie (AVRO) Neueste Nachrichten
10% Owner Leonard Braden Michael acquire 296882 shares of AvroBio Inc [AVRO] – Knox Daily - Knox Daily
Knox Daily
Investing in AvroBio Inc (AVRO) might be an excellent idea, but the stock is currently overvalued/undervalued – US ... - US Post News
US Post News
Avrobio executive buys shares worth over $970k - Investing.com India
Investing.com India
Financial Analysis: AVROBIO (NASDAQ:AVRO) versus SOPHiA GENETICS (NASDAQ:SOPH) - Defense World
Defense World
AVROBIO, Inc. (NASDAQ:AVRO) Major Shareholder Acquires $587,191.25 in Stock - MarketBeat
MarketBeat
Investors in cash trouble should check out AvroBio Inc (AVRO) – Sete News - SETE News
SETE News
AVROBIO, Inc. (NASDAQ:AVRO) Sees Significant Growth in Short Interest - MarketBeat
MarketBeat
AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 - MSN
MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO - The Malaysian Reserve
The Malaysian Reserve
AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC ... - Business Wire
Business Wire
AVROBIO (NASDAQ:AVRO) Shares Up 1.6% - Defense World
Defense World
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc ... - GlobeNewswire
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HireRight Holdings ... - GlobeNewswire
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ZeroFox Holdings ... - GlobeNewswire
GlobeNewswire
Avrobio's road ends in reverse merger with Tim Springer-backed startup - Yahoo Finance
Yahoo Finance
AVROBIO and Tectonic Therapeutic Announce Merger - Business Wire
Business Wire
Avrobio To Explore Strategic Alternatives - Contract Pharma
Contract Pharma
Avrobio stops programs, halves head count and searches for exit - Fierce Biotech
Fierce Biotech
Novartis Purchases Cystinosis Gene Therapy from AVROBIO - Pharmaceutical Technology Magazine
Pharmaceutical Technology Magazine
Novartis buys AVROBIO cystinosis gene therapy program for $87.5M - Labiotech.eu
Labiotech.eu
Avrobio agrees to sell cystinosis gene therapy to Novartis - Pharmaceutical Technology
Pharmaceutical Technology
Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf - Fierce Biotech
Fierce Biotech
Avrobio reports positive follow-up data for cystinosis gene therapy - Clinical Trials Arena
Clinical Trials Arena
Avrobio reports positive data from cystinosis gene therapy trial - Clinical Trials Arena
Clinical Trials Arena
Avrobio stock jumps 78% amid speculation of takeover interest - Seeking Alpha
Seeking Alpha
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory ... - Business Wire
Business Wire
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis - Business Wire
Business Wire
Cystinosis Pipeline Assessment | Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic ... - openPR
openPR
Avrobio receives orphan drug designation for gene therapy - Pharmaceutical Technology
Pharmaceutical Technology
UK MHRA approves Avrobio's Phase I/II Hunter syndrome therapy trial - Clinical Trials Arena
Clinical Trials Arena
Avrobio's gene therapy prompts positive phase I/II data in cystinosis - BioWorld Online
BioWorld Online
Avrobio Stopping Its Gene Therapy Program for Fabry Disease - Fabry Disease News
Fabry Disease News
Avrobio shares plummet as Fabry program axed, new trial starts slated for 2023 - Fierce Biotech
Fierce Biotech
University announces partnership with AVROBIO for Hunter syndrome gene therapy - The University of Manchester
The University of Manchester
Experts divided on Avrobio's phase two gene therapy for Fabry disease - Clinical Trials Arena
Clinical Trials Arena
AVROBIO: Promise In Fabry Disease (NASDAQ:AVRO) - Seeking Alpha
Seeking Alpha
Moving Average Crossover Alert: AVROBIO - Yahoo Lifestyle UK
Yahoo Lifestyle UK
AVROBIO, Inc. Announces Pricing of Initial Public Offering - GlobeNewswire
GlobeNewswire
Avrobio launches gene therapy program for Gaucher disease - Mass Device
Mass Device
Kapitalisierung:
|
Volumen (24h):